Program
In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries
of innovation to design an event that works in today’s quickly changing environment.
In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or
watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.
Common and Serious Complications Among Patients with Glycogen Storage Disease Type III (GSDIII)
Speaker(s)
Kruger E1, Nedzesky J1, Gupta RN2, Thomas NA2, Grimm AA2
1Ultragenyx Pharmaceutical Inc., San Francisco, CA, USA, 2Ultragenyx Pharmaceutical Inc., Novato, CA, USA
Presentation Documents
OBJECTIVES:
Glycogen Storage Disease Type III (GSDIII) is a rare inherited deficiency of glycogen-debranching enzyme characterized by organ dysfunction due to glycogen accumulation in tissues, as well as hypoglycemia. Current management practices to avoid hypoglycemia and preserve skeletal and cardiac muscles include a high-protein diet and uncooked cornstarch supplementation. This retrospective cohort study investigated common and serious complications among US patients with GSDIII.METHODS:
PearlDiver claims database with Mariner dataset was searched for patients diagnosed with GSDIII (ICD-10-D-E7403) and ≥12 months continuous enrollment in insurance between October 2015 and February 2020. A healthy comparator group was generated using propensity-score age- and sex-matching (1:20 ratio). Complications selected through literature review and expert clinical review were identified using ICD-10 diagnosis codes.RESULTS:
Overall, 230 patients with GSDIII and 4,600 comparators were included (female, 50%; mean age, 24.3 years; mean enrollment, 3.5 years). Complications were diagnosed among 96.1% of patients with GSDIII versus 74.8% of comparators. The most frequent complications among patients with GSDIII versus comparators were hepatomegaly (37.4% vs 0.6%), abdominal pain (36.5% vs 23.1%), hyperlipidemia (32.6% vs 16.2%), and nutritional deficiency (32.6% vs 12.3%). Additional serious complications were hypoglycemia (23.5% vs 0.9%), cardiomyopathy (14.3% vs 0.8%), liver cirrhosis (9.1% vs 0.3%), and rhabdomyolysis (6.5% vs <0.2%). Cardiovascular complications were frequent and included arrhythmia (18.7% vs 5.8%), cardiomegaly (17.0% vs 1.8%), heart valve disorder (10.0% vs 2.6%), and heart failure (6.5% vs 2.9%). Common musculoskeletal complications included muscle weakness (12.2% vs 2.8%) and myopathy (7.8% vs <0.2%). Psychiatric complications included anxiety (19.6% vs 15.6%) and depression (16.5% vs 12.5%). CONCLUSION: GSDIII is associated with high prevalence of complications, including serious cardiovascular, hepatic, and musculoskeletal manifestations. Nutritional and gastrointestinal complications were especially frequent and may be related to dietary management measures. These findings highlight the large unmet medical need for patients with GSDIII.Code
EPH47
Topic
Epidemiology & Public Health
Disease
Rare and Orphan Diseases